Eplontersen: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
[[File:Eplontersen.svg|thumb]]<br>Eplontersen | |||
Eplontersen, | |||
{{ | Eplontersen is a pharmaceutical compound under investigation for its potential therapeutic effects. It is primarily being studied for its role in treating certain genetic disorders. | ||
==Mechanism of Action== | |||
Eplontersen functions as an antisense oligonucleotide. Antisense oligonucleotides are short, synthetic strands of nucleic acids designed to bind to specific messenger RNA (mRNA) molecules. By binding to the mRNA, Eplontersen can modulate the expression of target genes, potentially reducing the production of harmful proteins associated with genetic disorders. | |||
==Therapeutic Applications== | |||
Eplontersen is being explored for its efficacy in treating transthyretin amyloidosis, a condition characterized by the accumulation of amyloid proteins in organs and tissues. This accumulation can lead to a variety of symptoms, depending on the organs affected. | |||
===Transthyretin Amyloidosis=== | |||
Transthyretin amyloidosis is a progressive disease that can affect the heart, nerves, and other organs. Eplontersen aims to reduce the production of transthyretin, the protein that misfolds and forms amyloid deposits. | |||
==Clinical Trials== | |||
Eplontersen is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are essential for determining the appropriate dosage and potential side effects of the drug. | |||
==Regulatory Status== | |||
As of the latest updates, Eplontersen has not yet received approval from major regulatory bodies such as the [[Food and Drug Administration]] (FDA) or the [[European Medicines Agency]] (EMA). It remains in the investigational stage. | |||
==Related Pages== | |||
* [[Antisense oligonucleotide]] | |||
* [[Transthyretin amyloidosis]] | |||
* [[Genetic disorders]] | |||
{{Drug-stub}} | |||
[[Category:Investigational drugs]] | |||
[[Category:Antisense therapy]] | |||
Latest revision as of 04:31, 9 January 2025
Eplontersen
Eplontersen is a pharmaceutical compound under investigation for its potential therapeutic effects. It is primarily being studied for its role in treating certain genetic disorders.
Mechanism of Action[edit]
Eplontersen functions as an antisense oligonucleotide. Antisense oligonucleotides are short, synthetic strands of nucleic acids designed to bind to specific messenger RNA (mRNA) molecules. By binding to the mRNA, Eplontersen can modulate the expression of target genes, potentially reducing the production of harmful proteins associated with genetic disorders.
Therapeutic Applications[edit]
Eplontersen is being explored for its efficacy in treating transthyretin amyloidosis, a condition characterized by the accumulation of amyloid proteins in organs and tissues. This accumulation can lead to a variety of symptoms, depending on the organs affected.
Transthyretin Amyloidosis[edit]
Transthyretin amyloidosis is a progressive disease that can affect the heart, nerves, and other organs. Eplontersen aims to reduce the production of transthyretin, the protein that misfolds and forms amyloid deposits.
Clinical Trials[edit]
Eplontersen is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are essential for determining the appropriate dosage and potential side effects of the drug.
Regulatory Status[edit]
As of the latest updates, Eplontersen has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It remains in the investigational stage.
